Business Context and Reporting Period
Envoy Medical, Inc. (Nasdaq: COCH) filed a Form 8-K on September 4, 2025, reporting the entry into a Material Definitive Agreement. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding a corporate agreement and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Agreements
On September 4, 2025, the Company entered into a Voting and Warrant Extension Agreement with Glen A. Taylor, GAT Funding, LLC, and Taylor Sports Group, Inc. (collectively, the "Taylor Parties"). Key terms include:
- Voting Commitment: The Taylor Parties, who beneficially own approximately 47.8% of the Company's Class A Common Stock, agreed to vote in favor of proposals required to ensure compliance with Nasdaq Listing Rules. This obligation is effective through December 31, 2028, and binds future transferees.
- Warrant Extension: The expiration date for 3,500,000 warrants held by GAT Funding, LLC (the "GAT Warrants") was extended to December 31, 2028. Previously, these warrants had expiration dates ranging from February 27, 2026, to June 26, 2027.
- Registration Rights: The Company granted registration rights to the Taylor Parties for the resale of their Class A Common Stock, exercisable upon request on or after March 31, 2026.
Outlook, Risks, and Management Commentary
The agreement is designed to support the Company's compliance with Nasdaq Listing Rules. The filing does not provide specific forward-looking guidance, management commentary on future operations, or a discussion of risks beyond the standard incorporation by reference of the full agreement.
Investor Verification Checklist
- Verify the current Nasdaq compliance status of Envoy Medical, Inc. and the specific listing rules addressed by the voting agreement.
- Confirm the total number of outstanding warrants and the dilution impact of the 3,500,000 GAT Warrants extended to 2028.
- Review the full text of the Voting and Warrant Extension Agreement (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Monitor the Company's stock price relative to the $11.50 exercise price of the Redeemable Warrants (COCHW) to assess the likelihood of warrant exercise.